The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'

RetroSense gets FDA orphan drug status for RST-001 to treat retinitis pigmentosa.....           Bristol-Myers Squibb expands manufacturing agreement with Lonza.....           GlaxoSmithKline introduces Incruse Ellipta in UK for COPD patients.....           Auspex begins Phase III AIM-TD trial of SD-809 in patients with tardive dyskinesia.....           Onxeo reports positive preliminary results from Validive Phase II trial for oral mucositis.....           AstraZeneca's XIGDUO XR combination diabetes drug gets FDA approval.....           SAFC introduces new protein quality supplement to increase N-linked Glycosylation.....           Protein Sciences gets FDA approval for Flublok influenza vaccine for adults aged 18 and older.....           Recro Pharma doses first patient in Phase II trial of Dex-IN to treat acute pain.....           Relmada adds $15m in capital to accelerate development of pain treatment drugs.....           MEI Pharma begins dosing in ME-344 Phase Ib trial for small cell lung and ovarian cancers.....           Kamada's Glassia gets FDA orphan drug status for GVHD treatment.....           FDA grants accelerated approval for Pfizer' meningococcal B vaccine Trumenba.....           CEO-hunting Sanofi tried to tempt AstraZeneca's Soriot: Bloomberg.....           Ex-Sanofi CEO Viehbacher in line for up to $7.8M cash payoff.....           Novo Nordisk quells diabetes pricing fears with 2015 growth forecast.....           Deal-hungry Perrigo elbows aside competitors for Omega Pharma.....           New-drug sales boost plus OTC buyout yields $53B forecast for Bayer.....           Copaxone, still growing, helps Teva pass Q3 estimates.....           Pfizer reports positive Phase IV trial results of Pristiq to treat sexual dysfunction in MDD patients.....           Xencor renegotiates XmAb5871 agreement with Amgen.....           Aileron Therapeutics secures $33m in series E financing to advance cancer drug development.....           Plandai secures approval in Uruguay to grow cannabis for medical research.....           EMA advises GSK on Ebola vaccine development plan.....           CEO-hunting Sanofi tried to tempt AstraZeneca's Soriot: Bloomberg.....           FDA grants fast track status for Araim's ARA290 to treat Sarcoidosis-associated SFN.....           OliPass, Bristol-Myers partner for PNA-based therapeutics.....           FDA clears ProMetic's IND for plasminogen to treat hypoplasminogenemia.....           Triphase, Celgene extend deal for IV formulation of marizomib and bevacizumab for glioblastoma.....           Sanofi canned its outspoken CEO. Will the board go French with a replacement?.....           Gilead misses the mark in Q3 due to Obamacare fee and dip in Sovaldi revenue.....           Like Novartis before it, AstraZeneca benefits big time from Ranbaxy issues.....           Bayer, Merck KGaA spend big bucks for market share in China.....           Pfizer CEO: 'No reason' we can't do an inversion deal, Treasury rules or no.....           A tale of 'two worlds' for Novartis respiratory launches in U.S. and EU.....           Diabetes pricing war? Sanofi, Lilly and Novo each have their ideas.....           Bristol-Myers Squibb signs $475m option agreement to acquire F-star and FS102.....           US Health Coalition issues important medicine safety tips for cold and flu sufferers.....           Gryphon Investors takes over majority stake in CB Fleet.....           Adamas expands phase III program with ADS-5102 to treat Levodopa-induced Dyskinesia in PD patients.....           WCCT Global announces involvement in H1N1 oral vaccine development.....           Curis announces allowance of US patent covering compounds targeting HDAC and PI3K activities in a single molecule.....           Iroko signs licensing deal with Aspen to market Zorvolex in Australia and New Zealand.....           Osteros begins Phase I trial of MBC-11 to treat cancer-induced bone disease.....           Sanofi board: We've dismissed CEO Chris Viehbacher.....           BioDelivery to develop injectable microparticle formulation of buprenorphine with Evonik for use in opioid dependence and pain.....           PlasmaTech, Norgine sign license deal to commercialize MuGard in Australia and New Zealand.....           Cancer Research UK, Leukaemia & Lymphoma Research partner for new blood cancer drugs.....           Drive AB consortium launched to develop economic models for pharmaceutical industry.....           CorMedix gets FDA nod to begin clinical trial for Neutrolin.....           UPDATED: Looming trouble in Sanofi's diabetes biz turns up the heat on CEO.....           Big relief for Takeda, Lilly as judge slashes $9B Actos award by 99%.....           Pfizer's Q3 beats, but flat sales mean CEO Read needs a big move.....           Novartis gets 4% sales lift as 'growth products' make good on their label.....           Is $200 a share from Valeant enough after Allergan's strong Q3?.....           Orphan drug prices on non-orphan meds? Gilead, this means you, PBM says.....           FDA grants breakthrough therapy status for Merck's lung cancer drug Keytruda.....           Amunix signs services and supply deal with University of Nebraska-Lincoln to produce GMP-Grade XTEN.....           Mersana, Takeda enter commercial license deal for new Fleximer antibody-drug conjugate.....           Octapharma's Octagam 10% now available for ordering in US.....           Roskamp Institute discovers new target for drugs to treat Alzheimer's disease.....           Fresenius Kabi launches Kabiven in US.....           Akebia reports positive top-line results from Phase IIb AKB-6548 anemia trial.....           Pharma's top 10 M&A deals of 2014's first half.....           Big trouble in Sanofi's diabetes biz sends shares reeling, despite earnings boost.....           Mundipharma's Targin receives CHMP positive opinion to treat restless legs syndrome.....           Australia's CSL agrees to buy Novartis? influenza vaccine business for $275m.....           Clinuvel gets EMA approval for Scenesse to treat erythropoietic protoporphyria.....           Fed up with Allergan obstinance, Valeant CEO says he'd hike bid past $200 a share.....           Don't fire me, Sanofi CEO tells board, amid tussle over strategy.....           Novartis unloads last piece of vaccines puzzle to CSL for $275M.....           Merck bogged down by slumping sales, but cuts deliver on profits.....           U.S. Attorney asks Novo Nordisk about plant in Denmark.....           Will buyers bite for Unipharm amid Russian M&A slow-down?.....           Bayer, Kyoto University partner on collaborative research projects.....           Contract Packaging Resources recalls Assured brand Naproxen Sodium tablets.....           CHMP recommends label update for Esbriet in idiopathic pulmonary fibrosis.....           Alternaturals plans for new manufacturing facility to meet expected revenue growth.....           Imprimis reports positive clinical findings of dropless cataract surgery.....           Lundbeck provides update on new drug application for intravenous carbamazepine.....           Baxter's Obizur gets FDA approval to treat adults with acquired hemophilia A.....           EMA committee issues positive opinion for Astellas' prostate cancer treatment enzalutamide.....           Zymeworks, Lilly extend deal for new bi-specific immunotherapies on Azymetric platform.....           Medivation licenses anti-PD-1 immune modulatory monoclonal antibody from CureTech.....           USPTO grants Epizyme with notices of allowance for patent applications covering PRMT5 inhibitors.....           Vaxart accelerates Ebola tablet vaccine development.....           Islet and BHV report two Phase IIb clinical trials of remogliflozin etabonate to treat type 2 diabetes.....           NICE recommends Bayer's rivaroxaban as option for secondary prevention in ACS.....           Relypsa submits NDA for FDA clearance of hyperkalemia treatment Patiromer FOS.....           Cytori gets FDA nod to resume enrolment in ATHENA cardiovascular trial.....           EMA committee recommends AstraZeneca's ovarian cancer drug Lynparza.....           Actavis primed for another deal, or two, or maybe three.....           What does Pfizer's $11B buyback mean for the chances of an AstraZeneca bid?.....           Shire poised to succeed as solo act post-AbbVie with solid Q3 earnings.....           EMA favors AstraZeneca's ovarian cancer drug Lynparza that FDA committee dissed.....           Yervoy, Sprycel, Eliquis jumps help Bristol-Myers beat Q3 estimates.....           Pfizer turns back Mylan's patent challenge to Sutent.....           Novartis reports positive results from two Phase III trials of secukinumab in ankylosing spondylitis.....           Zymeworks, Lilly extend deal for new bi-specific immunotherapies on Azymetric platform.....           Roche to invest $3.2bn in Basel site development.....           Certara gets FDA grant to improve Simcyp's MechDermA to permit drug bioequivalence assessment.....           Celgene's powerhouse Revlimid gets a little Q3 help from new friends Pomalyst, Otezla.....           Eli Lilly continues downward spiral in Q3 as generics slam Cymbalta, Evista sales.....           Medicines Company sues lawyers for busting Angiomax patent filing deadline.....           Leaping Soliris sales send Alexion's bottom line soaring.....           J&J Innovation taps Texas for its latest biotech startup incubator.....           U.K. watchdogs back Bayer's Xarelto for heart attack patients.....           RSS NEWSFEED....
APS PharmSci 2014
Declared Huge Success
Please browse some of the messages below from the Conference Science Chair, APS Chair and Chief Scientist regarding their positive experiences at the recent APS PharmSci Conference.

Message from Linda Hakes-Conference Science Chair
It was a tremendous honour to be asked to be the Conference Science Chair for PharmSci 2014 but also more than a little daunting. The previous holders of the position had helped to establish the meeting as the premier UK conference on the pharmaceutical sciences and I didn’t want to let the side down.

Message from Bill Dawson, Chair APS
PharmSci 2014 was a huge success. Attendance was excellent, content was good and participants were lively and engaged. My lasting memory of the conference this year was the quality and enthusiasm of the poster presenters. They were professional and their material was in many cases really novel and thought provoking. Those selected for podium presentations did really well, particularly those for whom it was their first occasion. I well remember my first communication which seemed a blur I was so nervous. I still have no idea whether I did well or not.

Message from Claire Thompson-APS Chief Scientist
The APS PharmSci conference was, once again, a huge success. Gathering more than 550 scientists from industry, academia and regulatory agencies, the conference showcased innovation in research, ranging from graphene to regenerative medicine and biopharmaceutics to theranostics.

Keep your eye open for more reports, photos, feedback from the conference to follow over the coming weeks.
Welcome to
The Academy of
Pharmaceutical Sciences
The Academy of Pharmaceutical Sciences is the professional body for the Pharmaceutical Sciences in United Kingdom. A Pharmaceutical Scientist is an individual who contributes to bringing a new drug from concept through to a medicinal product. This includes, but is not exclusive to, individuals in academia, industry, regulation, clinical research and manufacturing.

The mission of the Academy of Pharmaceutical Sciences is to champion innovation and opportunity in Pharmaceutical Sciences for the delivery of medicines.

In order to achieve this mission, our aims are to:

  • Promote the Pharmaceutical Sciences to stakeholders to facilitate understanding and achieve engagement
  • Share learning, drive collaboration, partnership and innovation
  • Deliver insights into industry and academic roles for aspiring scientists

Latest News
The European Paediatric Formulation Initiative (EuPFI) paediatric biopharmaceutics survey
The EuPFI (European Paediatric Formulation Initiative are looking to gather the views of biopharmaceuics scientists on the development of a paediatric biopharmaceutics classification system.. If you are an individual working in the area of biopharmaceutics, we would really appreciate your time in completing this short survey. Note that we would like individuals to complete this based on their own opinions and not necessarily those of their employer. Feel free to share this with others working in this area.. x . We anticipated that this will take 10-15 minutes and we plan to share our findings via the EuPFI but please leave your contact details within the questionnaire if you would like a direct mail regarding the output.. With many thanks for your time. The EuPFI Biopharmaceutics workstream.
Information Webinar ITT Modular Masters Formulation Consortium
Interested in Delivering the Modular Masters in Formulation Science and Technology? Information Webinars for Providers 10th and 13th October. You may have already heard about the Science Industry Partnership (SIP) and the innovative new Modular Masters Programme in Formulation Science and Technology. If not, you will find further details on the SIP website: x The process to select the provider or provider consortium which will deliver the full programme in collaboration with the SIP has now begun. There are opportunities for Higher Education Institutions (HEIs) as well as private sector and other educational providers to become involved. So if you are interested in finding out how you could become part of this exciting new programme then register now for one of our short briefing webinars to be held on Friday 10th October at 11.00 AM or Monday 13th October at 12.30 PM.. To register to attend, simply e-mail with your full contact details and preferred webinar date. We will send webinar joining details to registrants ahead of time.. We expect the formal application process to open at the end of October and close at the end of November. Final selection of the provider or provider consortium will be made in early January 2015.. We will also be helping provider consortiums to form by sharing contact details and areas of expertise of interested parties. If you would like your details to be shared in this way, please provide (by e-mail to a short description of topics, expertise and existing or planned relevant educational provision. If you are considering leading a consortium, you may also wish to indicate in which areas you require partners to fill any gaps in provision.. We look forward to speaking with you at one of the webinars... Tina Roberts Higher Education Development Manager Cogent Sector Skills Council Unit 5 Mandarin Court Centre Park Warrington WA1 1GG. Tel: 01925 515200 x301 Mobile: 07715014099 Fax: 01925 515240 Email: Web:
Unique leadership event for women in healthcare science leadership
The Academy of Pharmaceutical Sciences (APS) and Royal Pharmaceutical Society (RPS) are organising a symposium on the 7 October 2014 for women in healthcare science leadership.. The organisers have put together a panel of leading professionals to help women develop their careers and includes eminent speakers from across clinical pharmacy, academic research and industry. The event is attracting a wide audience of individuals involved in leadership in the healthcare science and we would love to see you there.. . Are you looking to take the next step in your career? Are you ready to set new challenges and enhance your leadership skills?. Join us to hear from inspiring leaders in academic research, clinical pharmacy, and industry.. Helen Gordon, Chief Executive, Royal Pharmaceutical Society, says: “Our Women in healthcare science leadership symposium is a new event, developed to support women in existing or aspiring leadership roles. Attending will provide you with the perfect opportunity to challenge what you know about yourself and develop practical skills that will support your career. I for one am looking forward to hearing from our great line-up of speakers, who I’m sure will inspire and motivate you to excel and lead others in your field.”. The symposium has great networking potential with speakers from across clinical pharmacy, academic research and life sciences including:. Cathy Mooney MRPharmS, Deputy Director of Quality and Safety, University College London Hospitals NHS Foundation Trust Harriet Fear, CEO, One Nucleus Helena Morrissey CBE, CEO, Newton and Founder 30% Club Philippa Roberts MRPharmS, Director of Pharmacy and Risk Management, Wirral University Teaching Hospital NHS Foundation Trust Themes include leadership, innovation and entrepreneurship. During the day, you will:. Learn how to develop your leadership skills and successfully drive your career forwards Identify the successes and challenges for women in the workplace Discuss real life experiences with leading healthcare practitioners Examine the benefits of diversity in the workplace Learn how to overcome the barriers (both real and perceived) to becoming a leader Learn how to influence at the most senior level and to build networks. There will also be a Q&A session, giving you the unique opportunity to ask specific questions relating to your career.. We aim to provide you with the skills and confidence to successfully drive your career forward. Don't miss out: view the full programme and register today.. -symposium.asputm_medium=email&utm_source=Royal+Pharmaceutical+Society &utm_campaign=4695578_Women+in+healthcare+event+-+generic&dm_i=EQ,2S N4Q,G415KU,A5V2J,1.
Award Winners at APS PharmSci 2014
APS Invited lecture at PharmSci Conference 2014 on Monday September 8th from 13.45-14.35. . The APS are pleased to announce that Abdul Basit will deliver the APS lecture this year entitled Gut instincts: explorations in intestinal physiology and drug delivery. The APS lecture award is sponsored by AstraZeneca and is awarded to nominated members of APS who have made outstanding scientific contribution in their work and are ambassadors in their area with an international reputation.. Abdul Basit holds the position of Professor of Pharmaceutics at the University College London (UCL) School of Pharmacy. He is also a Visiting Professor in the Faculty of Chemical and Pharmaceutical Sciences at the University of Chile. Furthermore, he holds an Honorary Research Fellow in Gastroenterology at the Wingate Institute of Neurogastroenterology, Queen Mary College, University of London.. Abdul's research sits at the interface between pharmaceutical science and gastroenterology, forging links between basic science and clinical outcomes. He leads a large and multi-disciplinary research group, and the goal of his work is to further the understanding of gastrointestinal physiology by fundamental research. So far, this knowledge has been translated into the design of new technologies and improved disease treatments, many of which are currently in late stage clinical trials.. Abdul is also the only non-North American scientist to receive the Young Investigator Award in Pharmaceutics and Pharmaceutical Technology from the American Association of Pharmaceutical Scientists (AAPS). Moreover, he is the founder and director of two spin-out companies, and serves on the scientific advisory boards of pharmaceutical companies, healthcare organisations and charitable bodies, including the Clinton Health Access Initiative (CHAI).. . Winner of the 2014 Royal Pharmaceutical Society Science Award announced. Professor Benjamin J. Whalley has been announced as winner of the 2014 Royal Pharmaceutical Society’s prestigious Science Award. The award will be presented at the APS PhamSci 2014 conference at the University of Hertfordshire, when Professor Whalley will deliver a plenary lecture on The therapeutic value of non-psychoactive components of cannabis in epilepsy: from lab to clinic.. The lecture will take place on Tuesday 9th September at 1335.. . . . The RPS Science Award has a long history with previous winners invariably going on to make significant contributions in the field of pharmaceutical science. The award is presented to a pharmaceutical scientist with no more than 10 years’ experience at post-doctoral level who has a proven record of independent research and published work that shows outstanding promise.. Professor Benjamin J. Whalley studies neuronal processes that underlie complex physiological functions, specifically neuronal hyperexcitability states and their consequential disorders (e.g. epilepsy, ataxia and dystonias). As a registered pharmacist (1992-present), Professor Whalley’s research in this area has primarily focused upon preclinical drug development in epilepsy. Here, he has primarily employed electrophysiological approaches with a variety of in vitro models of epileptiform activity and a number of in vivo rodent models of seizure and epilepsy.. He has used these approaches to examine the cellular and neuronal network mechanisms that underlie the effects of anti-epileptic drugs (AEDs) that are in clinical use or currently in clinical trials (e.g. levetiracetam (UCB Pharmaceuticals), carisbamate and topiramate (RW Johnson)). More recently, his work has examined the effects of several non-psychoactive components of marijuana (‘phytocannabinoids’) upon hyperexcitability states. Here, he has demonstrated that several of these phytocannabinoids exert significant anti-epileptic effects and, since 2008, has worked with GW Pharmaceuticals and Otsuka Pharmaceuticals to develop these drugs to the point of translation to human clinical trials. This work has yielded 4 international patents and, in 2013, initiation of Phase 1 human clinical trials for one drug (cannabidavarin) and Phase 2 human clinical trials for another (cannabidiol) in drug resistant, pediatric epilepsies. Early efficacy data from these trials has shown that cannabidiol has beneficial effects upon seizures in otherwise treatment-resistant paediatric epilepsy patients.. Prof. Whalley’s expertise in this area is further reflected in his role as an expert witness in criminal trials involving cannabis, his invited authorship of The American Herbal Pharmacopeia’s monograph on Cannabis and Epilepsy and recent appointment to the UK Advisory Council on the Misuse of Drugs. His work with non-psychoactive phytocannabinoids has also included work with colleagues which has revealed cannabinoid effects upon appetite and feeding behaviours, anti-ataxic mechanisms of action in the cerebellum and ongoing studies of the effect of these compounds in cachexic states.. A significant component of Prof. Whalley’s research has also been the development of experimental platforms which combine biological (e.g. neuronal cell culture, acute brain slices) and machine (e.g. robotic) systems to produce brain-machine interfaces (BMI) as tools for investigating the cellular correlates of complex CNS functions, including stem cell-based approaches. This research has thus far culminated in development of the first bioelectrically functional, 3D human neuronal network from stem cells, using biocompatible scaffolds; work featured in recent BBC science programming. This BMI research has formed part of presentations to the UK Cabinet Office and the US Senate, features in New Scientist, The Lancet, national broadsheets, national and international television and radio, an exhibit at the London Science Museum.. Both of the above research strands were chosen to act as two of the three Research Excellence Framework (REF) Impact Case Studies submitted by the Reading School of Pharmacy. Prof. Whalley has won ~£6M grant funding since taking up his first independent academic position in 2005 and his current grant funding supports a research group of 2 PDRAs and 9 PhD students. He has successfully supervised 13 PhD students to completion (100% success rate)..
Follow us
Upcoming Events
APS Drying Technologies for Biopharmaceuticals
28 January 2015
APS Industrial Insights 2015
16 - 17 April 2015
APS PharmSci 2015
7 - 9 September 2015
APS Pharmaceutical Photostability 2015
5 - 7 October 2015
APS Material Science
13 - 14 April 2015
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.


The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.